Xytis Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Xytis Pharmaceuticals Inc.
Past failures guide start-ups that seek to develop drugs for this silent epidemic, but will investors follow?
Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.
Xytis Pharmaceuticals Ltd., focused on in-licensing and developing late-stage CNS drug candidates, is taking a unique approach to treating schizophrenia by developing a drug that targets the NMDA receptor complex.
Start-ups in pursuit of novel targets are capturing the attention of venture capitalists.